MCID: PYR039
MIFTS: 42

Peyronie Disease

Categories: Rare diseases, Reproductive diseases

Aliases & Classifications for Peyronie Disease

MalaCards integrated aliases for Peyronie Disease:

Name: Peyronie Disease 56 74 52 54 71
Penile Curvature 52

Characteristics:

OMIM:

56
Inheritance:
male-limited, autosomal dominant


HPO:

31
peyronie disease:
Inheritance male-limited autosomal dominant


Classifications:



External Ids:

OMIM 56 171000
MedGen 41 C0030848
UMLS 71 C0030848

Summaries for Peyronie Disease

NIH Rare Diseases : 52 Peyronie disease is a connective tissue disorder characterized by a plaque, or hard lump, that forms within the penis. Affected individuals may experience painful, curved erections which can make make normal sexual intercourse impossible. Symptoms may appear suddenly or develop gradually. While the painful erections for most men resolve over time, the scar tissue and curvature may remain. Some cases appear to resolve spontaneously. The exact cause of Peyronie's disease is not known.

MalaCards based summary : Peyronie Disease, also known as penile curvature, is related to peyronie's disease and dupuytren contracture. An important gene associated with Peyronie Disease is IFNA2 (Interferon Alpha 2), and among its related pathways/superpathways are Pathways in cancer and Response to elevated platelet cytosolic Ca2+. The drugs Methyltestosterone and Testosterone undecanoate have been mentioned in the context of this disorder. Affiliated tissues include small intestine, prostate and skin, and related phenotypes are abnormality of the genitourinary system and dupuytren contracture

Wikipedia : 74 Peyronie's disease is a connective tissue disorder involving the growth of fibrous plaques in the soft... more...

More information from OMIM: 171000

Related Diseases for Peyronie Disease

Diseases in the Peyronie Disease family:

Peyronie's Disease

Diseases related to Peyronie Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 50)
# Related Disease Score Top Affiliating Genes
1 peyronie's disease 33.1 TGFB1 IFNA2
2 dupuytren contracture 31.8 TGFB1 DES
3 impotence 30.8 PDE5A NOS2
4 urethral stricture 30.2 TGFB1 PDE5A
5 priapism 30.0 PDE5A NOS2
6 vascular disease 29.6 TGFB1 SOD1 NOS2
7 ledderhose disease 11.2
8 hypospadias 10.8
9 sexual disorder 10.3
10 duplication of urethra 10.2
11 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.1
12 47,xyy 10.1
13 hypercholesterolemia, familial, 1 10.1
14 dowling-degos disease 1 10.1
15 trigeminal neuralgia 10.1
16 macular degeneration, age-related, 1 10.1
17 venous insufficiency 10.1
18 systemic scleroderma 10.1
19 essential tremor 10.1
20 compartment syndrome 10.1
21 diabetes mellitus 10.1
22 tremor 10.1
23 prostatitis 10.0 TGFB1 PDE5A
24 congenital heart defects, hamartomas of tongue, and polysyndactyly 9.9
25 cryptorchidism, unilateral or bilateral 9.9
26 leukemia, acute lymphoblastic 3 9.9
27 hydrops, lactic acidosis, and sideroblastic anemia 9.9
28 inguinal hernia 9.9
29 bladder exstrophy-epispadias-cloacal exstrophy complex 9.9
30 pulmonary edema 9.9
31 phimosis 9.9
32 48,xyyy 9.9
33 penoscrotal transposition 9.9
34 lymphedema 9.9
35 ureteral obstruction 9.9 TGFB1 NOS2
36 anoxia 9.9 SOD1 NOS2
37 eales disease 9.9 SOD1 NOS2
38 mucositis 9.9 TGFB1 NOS2
39 retinal vasculitis 9.9 SOD1 NOS2
40 pneumoconiosis 9.8 TGFB1 SOD1
41 chondromyxoid fibroma 9.8 TGFB1 DES
42 varicocele 9.8 SOD1 NOS2
43 toxoplasmosis 9.8 TGFB1 NOS2
44 penile disease 9.7 TGFB1 PDE5A IFNA2
45 chagas disease 9.7 TGFB1 NOS2
46 brain edema 9.7 SOD1 NOS2
47 cardiovascular system disease 9.4 SOD1 PDE5A NOS2
48 pre-eclampsia 9.4 SOD1 PDE5A NOS2
49 microvascular complications of diabetes 5 9.4 SOD1 NOS2
50 dilated cardiomyopathy 8.9 TGFB1 SOD1 NOS2 DES

Graphical network of the top 20 diseases related to Peyronie Disease:



Diseases related to Peyronie Disease

Symptoms & Phenotypes for Peyronie Disease

Human phenotypes related to Peyronie Disease:

31
# Description HPO Frequency HPO Source Accession
1 abnormality of the genitourinary system 31 HP:0000119
2 dupuytren contracture 31 HP:0005679

Symptoms via clinical synopsis from OMIM:

56
G U:
penile contracture

Limbs:
associated dupuytren contracture

Clinical features from OMIM:

171000

MGI Mouse Phenotypes related to Peyronie Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 muscle MP:0005369 8.92 DES NOS2 SOD1 TGFB1

Drugs & Therapeutics for Peyronie Disease

Drugs for Peyronie Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 35)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methyltestosterone Approved Phase 4 58-18-4 6010
2
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
3
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 6013 10204
4
Testosterone enanthate Approved Phase 4 315-37-7 9416
5 Antineoplastic Agents, Hormonal Phase 4
6 Anabolic Agents Phase 4
7 Hormone Antagonists Phase 4
8 Androgens Phase 4
9 Testosterone 17 beta-cypionate Phase 4
10 Hormones Phase 4
11
Lidocaine Approved, Vet_approved Phase 2 137-58-6 3676
12 Dermatologic Agents Phase 2
13 Analgesics Phase 2
14 Chlorhexidine gluconate Phase 2
15 Disinfectants Phase 2
16 Anti-Infective Agents Phase 2
17 Anti-Infective Agents, Local Phase 2
18
Tocopherol Approved, Investigational Phase 1 1406-66-2, 54-28-4 14986
19
Vitamin E Approved, Nutraceutical, Vet_approved Phase 1 59-02-9 14985
20
Ergocalciferol Approved, Nutraceutical Phase 1 50-14-6 5280793
21
Vitamin D Approved, Nutraceutical, Vet_approved Phase 1 1406-16-2
22
Calcium Approved, Nutraceutical Phase 1 7440-70-2 271
23 Tocotrienol Investigational Phase 1 6829-55-6
24 Trace Elements Phase 1
25 Vitamins Phase 1
26 Micronutrients Phase 1
27 Ergocalciferols Phase 1
28 Nutrients Phase 1
29 Vitamin D2 Phase 1
30 Protective Agents Phase 1
31 Tocopherols Phase 1
32 Tocotrienols Phase 1
33 Calciferol Phase 1
34 Antioxidants Phase 1
35 Calcium, Dietary Phase 1

Interventional clinical trials:

(show all 18)
# Name Status NCT ID Phase Drugs
1 Treatment Response to Xiaflex Based on Ultrasound Characterization of Plaque for Men With Peyronie's Disease Recruiting NCT03774264 Phase 4 Xiaflex
2 Xiaflex® Plus Testosterone Treatment Pilot Study Protocol A Six-month, Pilot Project of Testosterone Treatment in Subjects Who Are Undergoing Xiaflex® Therapy for the Treatment of Peyronie's Disease Recruiting NCT03815331 Phase 4 Xiaflex®;Aveed
3 A Phase 3b, Open-label Pilot Study to Evaluate the Safety and Effectiveness of up to Four Treatment Cycles of AA4500 in Combination With the ErecAid® Esteem® Manual Vacuum Therapy System in Men With Peyronie's Disease Completed NCT02267460 Phase 3
4 A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease Completed NCT01243411 Phase 3
5 A Phase 3, Double-blind, Randomized, Placebo-controlled Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease Completed NCT01221597 Phase 3
6 A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease Completed NCT01685437 Phase 3
7 A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for Up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease Completed NCT01221623 Phase 3
8 Dupuytren's Disease and Extracorporeal Shockwave Therapy (DupuyShock-2010) - a Randomized Trial Unknown status NCT01184586 Phase 2
9 A Phase 2b, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Effectiveness of AA4500 Administered Two Times a Week for Up to Three Treatment Cycles (2 x 3) in Subjects With Peyronie's Disease Completed NCT00755222 Phase 2
10 Management of Urethral Injury During Penile Prosthesis Implantation: Urethral Sterilization With Chlorhexidine Digluconate to Facilitate Primary Repair and Same-Session Implantation Recruiting NCT03614429 Phase 2 Chlorhexidine gel will be prepared according to an international product Instillagel®
11 An Open-Label, Nine-Month Randomized Controlled Study of Testosterone (Testopel) Pellets Plus Vitamin D and E Versus Vitamin D and E Alone for the Treatment of Peyronie's Disease Completed NCT01578473 Phase 1 Vitamin D2;Vitamin E;Testosterone Pellets
12 Evaluate the Safety and Feasibility of Injecting Placental Matrix-Derived Mesenchymal Stem Cells Into the Penis to Treat the Symptoms of Peyronie's Disease Completed NCT02395029 Phase 1
13 Efficacy of Penile Traction Therapy Using a Novel Device: A Controlled, Single-blinded, Randomized Trial Completed NCT03389854
14 Does Size Matter: A Single Case Experimental Design of Limiting the Depth of Penetration During Intercourse Completed NCT04052217
15 The Herlev Hospital Post Radiation Therapy for Localized Prostate Cancer Database for Sexual Side Effects Completed NCT02274350
16 Penile Length Maintenance Post-Prostatectomy Recruiting NCT03500419
17 A Prospective Randomized Double Blinded Placebo Controlled Clinical Trial Evaluating the Combined Effect of Low-Intensity Extracorporeal Shockwave Therapy (LI-ESWT) and Vacuum Erectile Device Combined With Manipulation Exercises on Peyronies Disease. Recruiting NCT03530540
18 Outcomes of Surgical Correction of Penile Curvature in Adult Not yet recruiting NCT03313986

Search NIH Clinical Center for Peyronie Disease

Genetic Tests for Peyronie Disease

Anatomical Context for Peyronie Disease

MalaCards organs/tissues related to Peyronie Disease:

40
Small Intestine, Prostate, Skin, Heart, Smooth Muscle, Bone, Kidney

Publications for Peyronie Disease

Articles related to Peyronie Disease:

(show top 50) (show all 906)
# Title Authors PMID Year
1
A brief historical survey of "Peyronie's disease". 56 61
18179461 2008
2
Peyronie's disease: advances in basic science and pathophysiology. 56
12084307 2000
3
A case-control study on risk factors for Peyronie's disease. 56
9636000 1998
4
Multiple clonal chromosome abnormalities in Peyronie's disease. 56
2021920 1991
5
Chromosome abnormalities in Peyronie's disease. 56
3560320 1987
6
Peyronie's disease: a newly recognized autosomal-dominant trait. 56
6213155 1982
7
Labetalol-induced Peyronie's disease? A case report. 56
231377 1979
8
Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie's disease. 61 54
16753449 2006
9
Evidence that osteogenic progenitor cells in the human tunica albuginea may originate from stem cells: implications for peyronie disease. 61 54
16093362 2005
10
The impact of intralesional interferon alpha-2b injection therapy on penile hemodynamics in men with Peyronie's disease. 54 61
16422829 2005
11
Intralesional interferon-alpha-2B injections for the treatment of Peyronie's disease. 54 61
14746421 2004
12
Intralesional interferon-alpha-2b for the treatment of Peyronie's disease. 54 61
12454683 2002
13
Combined intralesional interferon alpha 2B and oral vitamin E in the treatment of Peyronie's disease. 61 54
11519219 2001
14
A pilot study demonstrating clinical benefit from intralesional interferon alpha 2B in the treatment of Peyronie's disease. 61 54
10452584 1999
15
Penile deviation--our therapeutic concept. 61 54
7604623 1994
16
Radiation Therapy for Benign Disease: Keloids, Macular Degeneration, Orbital Pseudotumor, Pterygium, Peyronie Disease, Trigeminal Neuralgia. 61
31739946 2020
17
Penile Reconstructive Surgery in Peyronie Disease: Challenges in Restoring Normal Penis Size, Shape, and Function. 61
29623703 2020
18
Re: Comparison of Clinician and Patient Users of a Mobile Phone Application to Assess Penile Curvature in Peyronie's Disease. 61
31625787 2020
19
How Atypical Penile Curvature Influence Clinical Outcomes in Patients with Peyronie's Disease Receiving Collagenase Clostridium Histolyticum Therapy? 61
31190485 2020
20
Surgical Management of Peyronie's Disease With Co-Existent Erectile Dysfunction. 61
31540882 2019
21
Evaluation of Oral Pentoxifylline, Colchicine, and Penile Traction for the Management of Peyronie's Disease. 61
31445974 2019
22
Intraoperative methods for residual curvature correction during penile prosthesis implantation in patients with Peyronie's disease and refractory erectile dysfunction. 61
31754245 2019
23
Prevalence and surgical management of pubic hypertrophy in hypospadias patients: results from a high-volume surgeon. 61
31808413 2019
24
Impact of the Advent of Collagenase Clostridium Histolyticum on the Surgical Management of Peyronie's Disease: A Population-Based Analysis. 61
31759930 2019
25
A snapshot of intralesional verapamil injection in the treatment of Peyronie's disease today. 61
31475740 2019
26
Penile dimensions: What are surgeons measuring? 61
30932028 2019
27
Penile fracture and investigation of early surgical repair effects on erectile dysfunction. 61
31010389 2019
28
Collagenase Clostridium Histolyticum: A Review in Peyronie's Disease. 61
31628593 2019
29
Plication techniques in Peyronie's disease: new developments. 61
31582822 2019
30
Low-Intensity Shock Wave Therapy in Sexual Medicine-Clinical Recommendations from the European Society of Sexual Medicine (ESSM). 61
31447380 2019
31
Prevalence, assessment and surgical correction of penile curvature in hypospadias patients treated at one European Referral Center: description of the technique and surgical outcomes. 61
31654219 2019
32
Consulting "Dr Google" for sexual dysfunction: a contemporary worldwide trend analysis. 61
31591474 2019
33
Congenital prepubic sinus with dorsal penile curvature: a case report and literature review. 61
31640609 2019
34
Goniometer not better than unaided visual inspection at estimating ventral penile curvature on plastic models. 61
31680019 2019
35
Long-Term Results after Surgical Treatment of Congenital Penile Curvature Using a Modified Nesbit Technique. 61
31496150 2019
36
Medical Management of Peyronie's Disease: Review of the Clinical Evidence. 61
31540526 2019
37
Extracorporeal Shock Wave Therapy in Peyronie's Disease: Clinical Efficacy and Safety from a Single-Arm Observational Study. 61
30929330 2019
38
Surgical Treatment of Peyronie's Disease: Systematic Review of Techniques Involving or Not Tunica Albuginea Incision. 61
31570315 2019
39
The Effectiveness of 3-D Computed Tomography in the Evaluation of Penile Deformities in Patients With Peyronie's Disease: A Pilot Study. 61
31324507 2019
40
Outcomes of a Novel Penile Traction Device in Men with Peyronie's Disease: A Randomized, Single-Blind, Controlled Trial. 61
30916626 2019
41
Long-term intracavernosal injection therapy: treatment efficacy and patient satisfaction. 61
31477852 2019
42
Color Doppler Duplex Ultrasound Parameters in Men Without Organic Erectile Dysfunction. 61
31541647 2019
43
Novel approaches and new grafting materials in Peyronie's disease reconstructive surgery. 61
31383990 2019
44
Persistent or recurrent ventral curvature after failed proximal hypospadias repair. 61
31068257 2019
45
Use of small intestinal submucosa for corporal body grafting in cases of epispadias and epispadias/exstrophy complex. 61
31221598 2019
46
Megaprepuce: presentation of a modified surgical technique with excellent cosmetic and functional results. 61
31301977 2019
47
Testosterone Levels Are Not Associated With Magnitude of Deformity in Men With Peyronie's Disease. 61
31303573 2019
48
Current trends in the surgical treatment of congenital penile curvature. 61
31383991 2019
49
Re: Impact of Camera Deviation on Penile Curvature Assessment Using 2D Pictures. 61
30925090 2019
50
[Penile prosthesis implantation through subcoronal approach with graft-free corporoplasty in patients with Peyronie disease with concomitant erectile dysfunction]. 61
31356025 2019

Variations for Peyronie Disease

Expression for Peyronie Disease

Search GEO for disease gene expression data for Peyronie Disease.

Pathways for Peyronie Disease

GO Terms for Peyronie Disease

Cellular components related to Peyronie Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 secretory granule GO:0030141 8.62 TGFB1 SOD1

Biological processes related to Peyronie Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.5 TGFB1 NOS2 IFNA2
2 response to organic substance GO:0010033 9.43 TGFB1 SOD1
3 negative regulation of gene expression GO:0010629 9.43 TGFB1 NOS2 IFNA2
4 positive regulation of MAP kinase activity GO:0043406 9.4 TGFB1 PDE5A
5 negative regulation of T cell proliferation GO:0042130 9.37 TGFB1 PDE5A
6 muscle cell cellular homeostasis GO:0046716 9.16 TGFB1 SOD1
7 superoxide metabolic process GO:0006801 8.96 SOD1 NOS2
8 positive regulation of superoxide anion generation GO:0032930 8.62 TGFB1 SOD1

Sources for Peyronie Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....